Please assess the completion status of the following clinical trial:

Trial Title: A Phase II Trial of Calcitriol and Naproxen in Patients With Recurrent Prostate Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Must give written informed consent~* Histologically confirmed adenocarcinoma of the prostate~* Biochemical relapse after primary radiation therapy or surgery~* Normal testosterone levels~* 3 rising PSA after nadir, with interval between PSA determinations \> 2 weeks~Exclusion Criteria:~* Local recurrence by CT scan~* Distant metastases by bone scan~* Hypercalcemia~* Nephrolithiasis~* Renal insufficiency (serum creatinine \> 1.8 mg/dl)~* Pancreatitis~* History of ulcer or gastrointestinal bleeding~* More than 6 months of hormone ablation therapy~* Concurrent therapy for prostate cancer~* Uncontrolled HTN~* H/O MI, CVA, TIA~* Known coronary disease/cerebrovascular disease~* Platelet counts \<50~* Patients on anticoagulants~* Patients on lithium

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).